TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2447432

Group type: EXPERIMENTAL
Intervention: Nicorandil (20 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30265562

Group type: EXPERIMENTAL
Intervention: Switching from flash glucose monitoring to real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuing with RT-CGM for an additional 8 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Switching from flash to RT-CGM
Number of subjects: 40
Study: 29952503

Group type: EXPERIMENTAL
Intervention: Dietary counseling
Number of subjects: 50
Study: 24582471

Group type: EXPERIMENTAL
Intervention: High-carbohydrate hypercaloric tube-fed diet (HC/HC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (isocaloric tube-fed diet)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-fat hypercaloric tube-fed diet (HF/HC)
Number of subjects: 24
Study: 22633226

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) injections administered immediately following PNA and at 6 weeks and 3 months after the procedure.
Number of subjects: 47

Group type: COMPARATOR
Intervention: No injections (control group).
Number of subjects: 47
Study: 20555294

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 389
Study: 18986065

Group type: EXPERIMENTAL
Intervention: Moving target with a stationary object aligned with its initial location
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moving target without a stationary object
Number of subjects: 0
Study: 15932522

Group type: EXPERIMENTAL
Intervention: Cannabinoids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 12874489

Group type: EXPERIMENTAL
Intervention: Clonidine syrup 0.10 to 0.20 mg/day
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 10537782

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with benzoporphyrin derivative
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with tin ethyl etiopurpurin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8604626

Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg twice daily
Number of subjects: 56

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56
Study: 1429475

Group type: EXPERIMENTAL
Intervention: Gradual dawn simulation (2.5-hour duration)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Rapid dawn simulation (10-minute duration)
Number of subjects: 9
Study: 4044104

Group type: EXPERIMENTAL
Intervention: Caffeine trial (5 mg caffeine/kg body weight)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control trial (decaffeinated, calorie-free cola)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine trial
Number of subjects: 8
Study: 29052245

Group type: EXPERIMENTAL
Intervention: Probiotic and peanut oral immunotherapy (PPOIT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 27530657

Group type: EXPERIMENTAL
Intervention: Selenium 200 µg daily as selenized yeast
Number of subjects: 1621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1621
Study: 23963309

Group type: EXPERIMENTAL
Intervention: Low-dose drospirenone/estradiol (0.25 mg/0.5 mg and 0.5 mg/0.5 mg)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Estradiol (0.3 mg)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study: 22882843

Group type: EXPERIMENTAL
Intervention: Rosuvastatin loading before PCI (20 mg 12 hours before procedure, 10 mg 2 hours before procedure)
Number of subjects: 117

Group type: COMPARATOR
Intervention: No rosuvastatin treatment before PCI (control group)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Rosuvastatin loading before PCI
Number of subjects: 117
Study: 20156339

Group type: EXPERIMENTAL
Intervention: Personalized intervention combining web-based tailored lifestyle advice and personal counselling by a lifestyle coach
Number of subjects: 400

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 400
Study: 18216475

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream applied twice daily for 8 weeks
Number of subjects: 20
Study: 15591112

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) after myeloablative radiochemotherapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Alpha-interferon maintenance (IFN alpha)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 122
Study: 12851096

Group type: EXPERIMENTAL
Intervention: Gait test with burden
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Stair-climbing test
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: PILE cervical test
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: All tests
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Less fit subjects
Number of subjects: 186
Study: 10226898

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)-based immunosuppression
Number of subjects: 85

Group type: COMPARATOR
Intervention: Cyclosporine (CYA)-based immunosuppression
Number of subjects: 85
Study: 8556396

Group type: EXPERIMENTAL
Intervention: Early zidovudine treatment (n = 170)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Later zidovudine treatment (n = 168)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Early zidovudine treatment
Number of subjects: 275

Group type: COMPARATOR
Intervention: Later zidovudine treatment
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Patients receiving zidovudine for more than the median duration (20.3 months)
Number of subjects: 275
Study: 1853191

Group type: EXPERIMENTAL
Intervention: 10-week exercise-based cardiac rehabilitation programme
Number of subjects: 22

Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 22
Study: 6756774

Group type: EXPERIMENTAL
Intervention: T-Cu 380A
Number of subjects: 328

Group type: COMPARATOR
Intervention: Lippes loop C
Number of subjects: 328
Study: 31969652

Group type: EXPERIMENTAL
Intervention: Standard and strengthened care management (LA.S.S)
Number of subjects: 1419

Group type: COMPARATOR
Intervention: Standard care management (A.S)
Number of subjects: 1419

Group type: COMPARATOR
Intervention: Standard care management (LA.S)
Number of subjects: 1419
Study: 30717034

Group type: EXPERIMENTAL
Intervention: Various interventions related to management of hydrocephalus (e.g., shunt techniques, endoscopic treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-centered outcomes (e.g., neurodevelopmental assessment, quality of life)
Number of subjects: 0
Study: 29483383

Group type: EXPERIMENTAL
Intervention: Tongxinluo capsules (TCs)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 26856504

Group type: EXPERIMENTAL
Intervention: Caregiver-delivered reflexology
Number of subjects: 551
Study: 24150216

Group type: EXPERIMENTAL
Intervention: F-SHAI (SHAI with fludarabine, 15 mg/m(2), 4 h before cytarabine)
Number of subjects: 326

Group type: COMPARATOR
Intervention: SHAI (cytarabine, 1 g/m(2) bid, days 1‐2 and 8‐9; idarubicin 10 mg/m(2) daily, days 3‐4 and 10‐11)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: F-SHAI
Number of subjects: 326

Group type: COMPARATOR
Intervention: SHAI
Number of subjects: 326
Study: 22215436

Group type: EXPERIMENTAL
Intervention: Typical peer models
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-peer models
Number of subjects: 60
Study: 20837887

Group type: EXPERIMENTAL
Intervention: Yohimbine (5.4 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of pyridostigmine and yohimbine
Number of subjects: 31
Study: 17652682

Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 200

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 200
Study: 16135590

Group type: EXPERIMENTAL
Intervention: Outpatient treatment (single intramuscular injection of cefoxitin and oral doxycycline)
Number of subjects: 831

Group type: COMPARATOR
Intervention: Inpatient treatment (intravenous cefoxitin and doxycycline)
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 831
Study: 11856590

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with stem cell support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy in adjuvant setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy in inflammatory breast cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy after conventional treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of high-dose chemotherapy strategy
Number of subjects: 0
Study: 10205193

Group type: EXPERIMENTAL
Intervention: Atropine (15 microg/kg bolus, 4 microg/kg/h infusion)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methscopolamine bromide (MSB) (5 mg orally, four times daily for three days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 7594028

Group type: EXPERIMENTAL
Intervention: Arbutamine echocardiography
Number of subjects: 143

Group type: COMPARATOR
Intervention: Exercise echocardiography
Number of subjects: 143
Study: 2528386

Group type: COMPARATOR
Intervention: OK‐432
Number of subjects: 382

Group type: COMPARATOR
Intervention: sizofiran
Number of subjects: 382

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 382
Study: 31821151

Group type: EXPERIMENTAL
Intervention: Web-based unguided self-help intervention based on cognitive behavioral principles
Number of subjects: 2116

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 2116
Study: 30024447

Group type: EXPERIMENTAL
Intervention: Brace group (rigid brace full-time for 12 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No brace group (soft corset for 2 weeks, then weaned off)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Brace group
Number of subjects: 90

Group type: COMPARATOR
Intervention: No brace group
Number of subjects: 90
Study: 28017524

Group type: EXPERIMENTAL
Intervention: 2 μg paricalcitol (PCT)/day for 12 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PCT treatment
Number of subjects: 88
Study: 26780394

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (100 mg lactose)
Number of subjects: 60
Study: 23171573

Group type: EXPERIMENTAL
Intervention: 3 g tannin-rich fiber (low-dose group, n = 13)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5 g tannin-rich fiber (high-dose group, n = 13)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0 g (placebo group, n = 14)
Number of subjects: 40
Study: 21365166

Group type: COMPARATOR
Intervention: Program 1 (educational program)
Number of subjects: 4249

Group type: COMPARATOR
Intervention: Program 2 (active program)
Number of subjects: 4249
Study: 19034098

Group type: EXPERIMENTAL
Intervention: Order pattern analysis parameters (permutation entropy, recurrence rate, phase coupling)
Number of subjects: 2
Study: 17047607

Group type: EXPERIMENTAL
Intervention: Metrogil-denta with 25% metronidazole concentration
Number of subjects: 76

Group type: COMPARATOR
Intervention: Metrogil-denta with 1% metronidazole concentration
Number of subjects: 76
Study: 12916293

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alendronate and Risedronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of bisphosphonates with estrogen or raloxifene
Number of subjects: 0
Study: 10960393

Group type: EXPERIMENTAL
Intervention: Nerve stimulation (Group PNS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paresthesia elicitation (Group PAR)
Number of subjects: 100
Study: 8968661

Group type: EXPERIMENTAL
Intervention: 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days followed by 0.030 mg desogestrel for 7 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 1601378

Group type: EXPERIMENTAL
Intervention: Causal pharmacological treatment of disordered spermatogenesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical and microsurgical procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medicinal treatment for disturbances affecting the epididymis and other adnexa
Number of subjects: 0
Study: 6437092

Group type: EXPERIMENTAL
Intervention: TTS‐Nitroglycerin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 12
Study: 28901214

Group type: EXPERIMENTAL
Intervention: Total dose infusion (TDI) of low molecular weight (LMW) iron dextran
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral iron ferrous fumarate 60 mg elemental iron three times daily
Number of subjects: 66
Study: 30660136

Group type: COMPARATOR
Intervention: LSM and corn oil (1.5 g/day; placebo)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: LSM & n‐3 (EPA + DHA concentrate 1.5 g/day, containing 0.6 g EPA + DHA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: LSM
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: LSM & n‐3
Number of subjects: 34
Study: 26360140

Group type: EXPERIMENTAL
Intervention: Right lateral jack-knife position (RLJK) for 60 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: Right lateral decubitus position (RLD) for 60 minutes
Number of subjects: 50
Study: 24685971

Group type: EXPERIMENTAL
Intervention: Sumatriptan 85/naproxen sodium 500
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22444781

Group type: EXPERIMENTAL
Intervention: Copper supplementation (2 mg copper/day as copper glycinate) for 8 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20176277

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 28
Study: 17571965

Group type: EXPERIMENTAL
Intervention: Very low-fat vegan diet supplemented with soy protein (58 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care controls
Number of subjects: 0
Study: 15709054

Group type: EXPERIMENTAL
Intervention: Differential path-length spectroscopy (DPS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal mucosa
Number of subjects: 64
Study: 12224093

Group type: EXPERIMENTAL
Intervention: KTP (532 nm) laser treatment
Number of subjects: 70
Study: 10223495

Group type: EXPERIMENTAL
Intervention: Tolterodine 0.5 mg twice daily
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Tolterodine 1 mg twice daily
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg twice daily
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 7799029

Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) at a dose of 1.5 g/m2 in 100 mL of normal saline solution over a 15‐minute period immediately before CDDP administration, and at a dose of 600 mg by intramuscular injection on days 2 to 5.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline solution (placebo).
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Glutathione (GSH).
Number of subjects: 50
Study: 2325000

Group type: EXPERIMENTAL
Intervention: Memory aids (MA: n = 36)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No memory aids (NMA: n = 35)
Number of subjects: 71
Study: 391050

Group type: EXPERIMENTAL
Intervention: Polycon lenses
Number of subjects: 5

Group type: COMPARATOR
Intervention: PMMA lenses
Number of subjects: 5

Group type: COMPARATOR
Intervention: BP Flex lenses
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Steeper‐fitting PMMA lenses
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Steeper‐fitting BP Flex lenses
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Steeper‐fitting Polycon lenses
Number of subjects: 5
Study: 31347411

Group type: EXPERIMENTAL
Intervention: Health education intervention for caregivers, including a health education booklet and individual explanation
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Health education intervention for caregivers
Number of subjects: 177
Study: 30946273

Group type: EXPERIMENTAL
Intervention: Football prediction equation for V[Combining Dot Above]O2max using treadmill exercise time (Tmin)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Foster prediction equation for V[Combining Dot Above]O2max
Number of subjects: 472

Group type: COMPARATOR
Intervention: Bruce prediction equation for V[Combining Dot Above]O2max
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Football prediction equation for V[Combining Dot Above]O2max
Number of subjects: 472
Study: 27943425

Group type: EXPERIMENTAL
Intervention: Acitretin
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 289
Study: 26834282

Group type: EXPERIMENTAL
Intervention: Pumpless group (PL group: blood cardioplegia administration without roller pump)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Roller pump group (RP group: blood cardioplegia administration with roller pump)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Pumpless group (PL group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Roller pump group (RP group)
Number of subjects: 68
Study: 24392604

Group type: EXPERIMENTAL
Intervention: Lifestyle Self-Efficacy Scale for Latinos with Diabetes (LSESLD)
Number of subjects: 252
Study: 20811299

Group type: EXPERIMENTAL
Intervention: Myo-inositol (2 g BID plus diet)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (diet plus placebo)
Number of subjects: 80
Study: 19356420

Group type: EXPERIMENTAL
Intervention: Contrast agent use during dobutamine stress echocardiography (DSE)
Number of subjects: 101
Study: 16237629

Group type: EXPERIMENTAL
Intervention: Nursing instruction
Number of subjects: 0
Study: 11875694

Group type: EXPERIMENTAL
Intervention: Intratumoural/intrapleural SRL172 (1 microg to 1 mg) and intradermal SRL172 (1 mg) with standard chemotherapy (mitomycin‐C: 8 mg m(‐2), vinblastine: 6 mg m(‐2), cisplatin: 50 mg m(‐2))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard chemotherapy (mitomycin‐C, vinblastine, cisplatin)
Number of subjects: 16
Study: 10445196

Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: diclofenac sodium
Number of subjects: 97

Group type: COMPARATOR
Intervention: moist drops (control)
Number of subjects: 97
Study: 8636518

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSb)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSb + 5)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: External PEEP (PEEPe) of 75% of static intrinsic PEEP during PSb
Number of subjects: 10
Study: 2276936

Group type: EXPERIMENTAL
Intervention: Inflatable constricting device applied to the proximal aspect of the arm, inflated to 80 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflatable constricting device applied to the proximal aspect of the arm, inflated to 100 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflatable constricting device applied to the proximal aspect of the arm, inflated to 20 mm Hg
Number of subjects: 0
Study: 117492

Group type: EXPERIMENTAL
Intervention: Deanol acetamidobenzoate, administered in doses up to 1.5 g q.d. for three weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30477998

Group type: EXPERIMENTAL
Intervention: Companion present during neuraxial catheter placement
Number of subjects: 143

Group type: COMPARATOR
Intervention: Companion not present during neuraxial catheter placement
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both groups (companion present and not present)
Number of subjects: 143
Study: 27212001

Group type: EXPERIMENTAL
Intervention: 67% sodium bicarbonate toothpaste
Number of subjects: 148

Group type: COMPARATOR
Intervention: 0% sodium bicarbonate toothpaste
Number of subjects: 148
Study: 26352896

Group type: EXPERIMENTAL
Intervention: sirolimus‐eluting stent
Number of subjects: 170

Group type: COMPARATOR
Intervention: biolimus‐eluting stent
Number of subjects: 170
Study: 23432593

Group type: EXPERIMENTAL
Intervention: MI+HealthCall
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: MI-only
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control
Number of subjects: 258
Study: 20680671

Group type: EXPERIMENTAL
Intervention: Mother and father as caregivers
Number of subjects: 784

Group type: COMPARATOR
Intervention: Mother and grandparents as caregivers
Number of subjects: 784
Study: 18797946

Group type: EXPERIMENTAL
Intervention: Solis cage, Stryker Company
Number of subjects: 60

Group type: COMPARATOR
Intervention: Shell cage, AMT Company
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 17868841

Group type: EXPERIMENTAL
Intervention: Interscalene block
Number of subjects: 56

Group type: COMPARATOR
Intervention: Continuous infusion of 0.5% bupivacaine via pain pump for 48 hours
Number of subjects: 56
Study: 15328325

Group type: EXPERIMENTAL
Intervention: Telephone psychotherapy
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Telephone care management
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 600
Study: 11454528

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) - 5,000 IU intravenous bolus and continuous infusion of 18 IU/Kg/h (n=11)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enoxaparin - 1 mg/kg/12h subcutaneous (n=13)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control subjects (not treated with UFH or enoxaparin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: UFH and enoxaparin (combined)
Number of subjects: 24
Study: 9875837

Group type: EXPERIMENTAL
Intervention: Tamoxifen for an additional 5 years
Number of subjects: 1172

Group type: COMPARATOR
Intervention: Placebo for an additional 5 years
Number of subjects: 1172
Study: 7809316

Group type: EXPERIMENTAL
Intervention: Opening-up meditation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 3293399

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76